The results are an outcome of the company's focus on sustainable and profitable growth and reflects all the hard work and focus teams have put in over the years
Revolutionary technology will further boost OneSource’s scientific services offerings
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
The drug will be marketed in different strengths of 150 mg and 440 mg and used in the treatment of patients with HER2
The pooled prevalence of GERD in the Indian population is 15.6 %
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program
Subscribe To Our Newsletter & Stay Updated
